Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
Subscribe To Our Newsletter & Stay Updated
